Carton (Carton Label Page 1)
This is not-readable.*
Subvenite Suspension
Product Images NDC 69102-418
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Subvenite (NDC 69102-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Owp Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Container (Container Label)
This is a description of a medication called "Subvenite" (lamotrigine) oral suspension. Each mL contains lamotrigine USP equivalent to 10mg of lamotrigine. It is for oral use only and should be shaken well before each use. The medication guide should be given to each patient. The storage temperature should be between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Unused product should be discarded after ninety days of first opening the bottle. Additionally, a warning is given to keep this and all medications out of the reach of children. The recommended dosage information should be consulted for details. Made in the USA.*
Figure-1 (Figure 1 Subvenite 1)
This text appears to show a graph or data related to the failure probability of Lamotrigine compared to Placebo. The graph seems to display percentages ranging from 10% to 100%. The presence of the word "Censored" suggests that some data points may have been omitted or redacted for specific reasons.*
Figure-2 (Figure 2 Subvenite 1)
Owp Logo (Logo Owp)
Structure (Structure 1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
